Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial. - Huang, Haichao; Wang, Tao; Li, Wei; Wu, Zhun; Wang, Xuegang; Xing, Jinchun; Chen, Bin; Zhang, Kaiyan (BMC Cancer, 2025)